Table 2.
Primary Lung Cancer and Brain Metastasis PD-L1 Expression and Discordance Status
| Author | Year | N | Assay name | Criteria for PD-L1 expression measurement | PDL1 expression in TC (Lung) | PDL1 expression in TIL (Lung) | PDL1 in lung | PDL1 expression in TC (BM) | PDL1 expression in TIL (BM) | PDL1 in BM | Concordance in Lung/BM PDL1 TC (n [%]) | Discordance in Lung/BM PDL1 TC (n [%]) | Concordance in Lung/BM PDL1 TIL (n [%]) | Discordance in Lung/BM PDL1 TIL (n [%]) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <1 | 1 to 50 | >50 | <1 | 1 to 50 | >50 | Positive | Negative | <1 | 1 to 50 | >50 | <1 | 1 to 50 | >50 | Positive | Negative | |||||||||
| Mansfield et al.16 | 2016 | 73 | Leica Bond RX stainer | PDLI in >5% | NA | NA | NA | NA | NA | NA | 32 | 41 | NA | NA | NA | NA | NA | NA | 24 | 49 | 63 (86%) | 10 (14%) | 54 (74%) | 19 (26%) |
| Bherghoff et al. 17 | 2016 | 32 | Dako assay/ IHC | PDLI in >5% | NA | NA | NA | NA | NA | NA | 24 | 8 | NA | NA | NA | NA | NA | NA | 11 | 21 | 22 (70%) | 10 (30%) | NA | NA |
| Takamori et al. 18 | 2018 | 15 | Dako assay/ IHC | PDLI in >5% | 10 | 3 | 2 | NA | NA | NA | 4 | 11 | 11 | 1 | 3 | NA | NA | NA | 3 | 12 | 11 (75%) | 4 (25%) | NA | NA |
| Zhou et al. 19 | 2018 | 25 | Shuwen Biotech Co | PDLI in >5% | NA | NA | NA | NA | NA | NA | 17 | 8 | NA | NA | NA | NA | NA | NA | 16 | 9 | 18 (72%) | 7 (28%) | 15 (60%) | 10 (40%) |
| Teglasi et al. 20 | 2019 | 61 | Ventana | PDL1 for Tumor Cell 1%, 5%, and 50% | 39 | 18 | 4 | 34 | 20 | 6 | 61 | 0 | 40 | 10 | 11 | 38 | 19 | 4 | 61 | 0 | NA | NA | NA | NA |
| Batur et al. 10 | 2019 | 24 | Dako assay/ IHC | PDL1 for Tumor Cell 1%, 5%, and 50% | 6 | 9 | 9 | 6 | 13 | 5 | 18 | 6 | 7 | 9 | 8 | 6 | 16 | 2 | 17 | 7 | 23 (98%) | 1 (2%) | 23 (98%) | 1 (2%) |
BM, brain metastasis; IHC, immunohistochemistry; N, number; NA, not available; PD-L1, programmed death-ligand 1; TC, tumor cell; TIL, tumor-infiltrating lymphocytes.